Ciclesonide
| 證據等級: L5 | 預測適應症: 6 個 |
目錄
Using the txgnn-pipeline skill to guide the report structure, and now generating the evaluation report from the Evidence Pack.
Ciclesonide: From Asthma to Atopic Eczema
One-Sentence Summary
Ciclesonide is an inhaled/intranasal corticosteroid (ICS) globally approved for asthma maintenance and allergic rhinitis, though it currently has no registered products in Taiwan. The TxGNN model predicts it may be effective for Atopic Eczema, based on its glucocorticoid receptor (GR) agonism overlapping with the Th2-driven inflammatory pathway central to this condition. However, no clinical trials and no publications have been identified to support this specific pairing — this prediction is entirely model-driven at this stage (L5 evidence).
Quick Overview
| Item | Content |
|---|---|
| Original Indication | Asthma / Allergic Rhinitis (global approvals; no Taiwan registration) |
| Predicted New Indication | Atopic Eczema |
| TxGNN Prediction Score | 99.96% |
| Evidence Level | L5 (Model prediction only — no clinical studies identified) |
| Taiwan Market Status | ✗ Not Marketed |
| Number of Licenses | 0 |
| Recommended Decision | Hold |
Why is This Prediction Reasonable?
Detailed mechanism of action data was not available in this dataset. Based on established pharmacology, ciclesonide is a pro-drug activated by tissue esterases into its active metabolite des-ciclesonide. Des-ciclesonide is a potent glucocorticoid receptor (GR) agonist that suppresses expression of pro-inflammatory cytokines — particularly IL-4, IL-13, IL-31, and TNF-α — by binding to GR in target tissue and blocking NF-κB and AP-1 transcription.
Atopic eczema (atopic dermatitis, AD) is driven by a Th2-skewed immune response, in which IL-4 and IL-13 are the dominant mediators of epidermal barrier dysfunction and chronic inflammation. IL-31 is the primary itch-signalling cytokine in AD. This mechanistic overlap is direct and substantial — suppressing precisely the cytokines that drive AD pathology is the same mechanism by which corticosteroids exert their effect on respiratory inflammation. As a drug class, topical corticosteroids (TCS) are the global first-line standard of care for AD, making the TxGNN model’s cross-disease prediction mechanistically coherent.
The critical practical barrier, however, is route of administration. Ciclesonide currently exists only as an inhaled metered-dose inhaler (MDI) and intranasal spray. There is no approved topical skin formulation. While skin esterases are capable of activating ciclesonide prodrug in theory, this has not been demonstrated in a dermatological delivery system. Until a topical formulation is validated, the mechanistic link — though strong on paper — cannot be translated into clinical practice.
Clinical Trial Evidence
Currently no related clinical trials registered.
Literature Evidence
Currently no related literature available.
Note on adjacent predictions: While the top indication (atopic eczema) has no captured evidence, a closely related prediction — bronchitis (rank 4) — has one supporting guideline (PMID 25515181, Finnish COPD guideline, 2015), consistent with ciclesonide’s known role as an approved asthma ICS and the mechanistic overlap with chronic airway inflammation. Additionally, contact dermatitis (rank 5) has one captured case report (PMID 22957490, 2012) — notably a negative safety signal: a patient sensitised to budesonide showed cross-reactivity with ciclesonide on patch testing, suggesting ciclesonide may itself trigger corticosteroid contact allergy in sensitised individuals.
Taiwan Market Information
Ciclesonide currently has no registered products in Taiwan. No license information is available.
Safety Considerations
Please refer to the package insert for safety information.
Additional signal from adjacent evidence: PMID 22957490 (Contact Dermatitis, 2012) documents a case of systemic allergic dermatitis caused by inhaled budesonide with positive patch test cross-reactivity to ciclesonide. This is relevant if ciclesonide is considered for any dermatological indication — patients with prior corticosteroid sensitisation (Group B corticosteroids including budesonide) should be considered at risk for cross-reaction. This is a clinically important safety flag that distinguishes ciclesonide from other TCS options in AD.
Conclusion and Next Steps
Decision: Hold
Rationale: The mechanistic rationale for ciclesonide in atopic eczema is pharmacologically sound — GR agonism suppressing Th2/IL-4/IL-13/IL-31 inflammation is precisely the target in AD — but no clinical trials, observational studies, or publications have been identified to validate this application. Critically, no topical skin formulation exists, which is a prerequisite for dermatological use. The existing literature also raises a cross-reactivity safety concern in corticosteroid-sensitised patients.
To proceed, the following is needed:
- Formulation feasibility study: Assess whether a topical des-ciclesonide or ciclesonide cream/ointment can be developed with adequate skin penetration and local activation
- Preclinical evidence: In vitro and in vivo (AD mouse model) studies demonstrating anti-inflammatory efficacy via topical delivery
- MOA documentation: Retrieve full mechanism of action data from DrugBank (DB01410) to complete mechanistic linkage analysis
- Safety profiling: Obtain Taiwan (and US FDA) package insert data; document corticosteroid cross-reactivity class membership to assess dermatitis sensitisation risk
- Patch test sensitivity screen: If clinical development proceeds, include corticosteroid patch test panel screening as an eligibility criterion
Disclaimer
This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.